Last reviewed · How we verify
CAB OLI
CAB OLI is a long-acting injectable combination of cabotegravir and bictegravir that inhibits HIV integrase and reverse transcriptase to suppress viral replication.
CAB OLI is a long-acting injectable combination of cabotegravir and bictegravir that inhibits HIV integrase and reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable maintenance therapy).
At a glance
| Generic name | CAB OLI |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | Integrase inhibitor + nucleotide reverse transcriptase inhibitor combination |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating its genetic material into host cell DNA. Bictegravir is a nucleotide reverse transcriptase inhibitor (NtRTI) that blocks the enzyme responsible for converting viral RNA to DNA. Together, these agents provide dual-mechanism antiretroviral activity in a long-acting formulation administered via intramuscular injection.
Approved indications
- HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable maintenance therapy)
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea
Key clinical trials
- A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (PHASE4)
- Improving HIV-1 Control in Africa with Long Acting Antiretrovirals (PHASE3)
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (PHASE3)
- A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAB OLI CI brief — competitive landscape report
- CAB OLI updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI